DOCSLIB.ORG

Complexing with the Natural Anti-Gal Antibody REVIEW AR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Complexing with the Natural Anti-Gal Antibody REVIEW AR Uri Galili. Medical Research Archives vol 9 issue 7. Medical Research Archives REVIEW ARTICLE Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune- Complexing with the Natural Anti-Gal Antibody Author Uri Galili Department of Medicine, Rush Medical College, Chicago, IL, USA 910 S. Michigan Avenue, Apt. 904 Chicago, IL 60605 USA Email: [email protected] Abstract The appearance of variants of mutated virus in course of the Covid-19 pandemic raises concerns regarding the risk of possible formation of variants that can evade the protective immune response elicited by the single antigen S-protein gene-based vaccines. This risk may be avoided by inclusion of several antigens in vaccines, so that a variant that evades the immune response to the S-protein of SARS-CoV-2 virus will be destroyed by the protective immune response against other viral antigens. A simple way for preparing multi-antigenic enveloped-virus vaccines is using the inactivated whole-virus as vaccine. However, immunogenicity of such vaccines may be suboptimal because of poor uptake of the vaccine by antigen- presenting-cells (APC) due to electrostatic repulsion by the negative charges of sialic-acid on both the glycan-shield of the vaccinating virus and on the carbohydrate-chains (glycans) of APC. In addition, glycan-shield can mask many antigenic peptides. These effects of the glycan-shield can be reduced and immunogenicity of the vaccinating virus markedly increased by glycoengineering viral glycans for replacing sialic-acid units on glycans with -gal epitopes (Gal1-3Gal1-4GlcNAc-R). Vaccination of humans with inactivated whole-virus presenting -gal epitopes (virus-gal) results in formation of immune- complexes with the abundant natural anti-Gal antibody that binds to viral -gal epitopes at the vaccination site. These immune-complexes are targeted to APC for rigorous uptake due to binding of the Fc portion of immunocomplexed anti-Gal to Fc receptors on APC. The APC further transport the large amounts of internalized vaccinating virus to regional lymph nodes, process and present the virus antigenic peptides for the activation of many clones of virus specific helper and cytotoxic T-cells. This elicits a protective cellular and humoral immune response against multiple viral antigens and an effective immunological memory. The immune response to virus-gal vaccine was studied in mice producing anti-Gal and immunized with inactivated influenza-virus-gal. These mice demonstrated 100-fold increase in titer of the antibodies produced, a marked increase in T-cell response, and a near complete protection against challenge with a lethal dose of live influenza-virus, in comparison to a similar vaccine lacking -gal epitopes. This glycoengineering can be achieved in vitro by enzymatic reaction with neuraminidase removing sialic-acid and with recombinant 1,3galactosyltransferase (1,3GT) synthesizing -gal epitopes, by engineering host-cells to contain several copies of the 1,3GT gene (GGTA1), or by transduction of this gene in a replication-defective adenovirus vector into host-cells. Theoretically, these methods for increased immunogenicity may be applicable to all enveloped viruses with N-glycans on their envelope. Keywords: Inactivated whole-virus vaccine, vaccine immunogenicity, -gal epitope, natural anti-Gal antibody, glycan-shield, enveloped virus vaccines, variants. Copyright 2021 KEI Journals. All Rights Reserved Uri Galili. Medical Research Archives vol 9 issue 7. July 2021 Page 2 of 19 The variants conundrum in gene-based vs. enable virus escape from cytolytic T whole-virus vaccines lymphocyte (CTL) activity which causes the The current Covid 19 pandemic illustrates a lysis of cells infected with the non-mutated new conundrum in the area of vaccine virus.2 Another HIV variant acquired an preparation against enveloped viruses that additional carbohydrate chain (glycan) on its cause present and future pandemics: The use envelope gp120 portion of gp160.3 Gp120 has of gene-based vaccines or of vaccines made of 24 asparagine (N) linked carbohydrate chains inactivated whole-virus (referred to as (referred to as N-glycans) which inactivated virus vaccine). Inactivated virus “camouflage” (mask) a large proportion of the vaccines in the form of whole-virus or as virus antigenic peptides and are referred to as the disrupted by a detergent have been the “glycan-shield”.3-6 Synthesis of glycans due to traditional types of viral vaccines. The mutations that form more glycosylation sites efficacy of such vaccines and the duration of (i.e., the sequon N-X-S/T) contributes to the immune protection varies from one type of additional masking of gp120 antigens and vaccine to the other and accordingly, the thus, to evasion from the anti-HIV frequency of boosts required for maintaining neutralizing antibodies.3 the protective anti-viral immune response. In The S-protein of SARS-CoV-2 has 22 contrast, gene-based vaccines which recently N-glycans.7,8 Since the virus has the tendency have been widely used for Covid-19 vaccines to acquire random mutations in the course of are comprised of nucleic acid (DNA or replication, it may be able to undergo selective mRNA) of the S-protein gene (the gene “mutating evolution”, similar to that observed encoding the major envelope glycoprotein). in HIV. Such a selective process may result in The gene is delivered into muscle tissue as appearance of variants with increased number DNA within a replication defective viral of glycans, or in changes in antigenic structure vector, such as replication defective of the S-protein. In vaccinated individuals, adenovirus, or as mRNA within lipid both types of mutations may enable evasion of nanoparticles. This gene encodes for the variant from neutralizing anti-S-protein production of the vaccinating S-protein by antibodies or from anti-S-protein CTL. myotubes. These vaccines have been Variants that can evade the protective immune produced in large amounts within a period of response against the S-protein may less than one year and have demonstrated very accidentally appear in unimmunized good efficacy in protecting vaccinated individuals and subsequently infect individuals against infection by SARS-CoV- individuals vaccinated with gene-based 2. However, these gene-based vaccines seem vaccines containing only the S-protein gene. to be associated with the appearance of Variants resistant to the protective anti-S- mutated virus strains (called variants) with protein immune response may selectively higher infectivity (transmissibility) and/or expand in infected immunized individuals virulence, thereby increasing their ability to and further spread in immunized and non- survive and spread in populations.1 immunized populations. The appearance of Appearance of such variants has been a very such detrimental variants may be avoided by rare event in populations vaccinated by more including several antigens in the vaccine traditional methods, such as whole-virus (multi-antigenic vaccine). The production of vaccines or vaccines containing the virus antibodies and virus specific CTL against disrupted by detergents. Previous examples several viral antigens will markedly decrease for viral variants have been reported in HIV the probability for appearance of variants with patients in whom the virus mutated in course mutations evading the immune response of the infection.2,3 One amino acid mutation in against a single vaccinating viral antigen. the envelop glycoprotein gp160 was found to Such mutated SARS-CoV-2 viruses will be Copyright 2021 KEI Journals. All Rights Reserved htttp://journals.ke-i.org/index.php/mra Uri Galili. Medical Research Archives vol 9 issue 7. July 2021 Page 3 of 19 destroyed by the protective immune response inactivated whole-virus vaccine are against additional viral antigens, e.g., associated with the glycans on the viral antibodies against other envelope proteins and envelope glycoproteins. These are: 1. CTL recognizing antigenic peptides of the Generation of a negative electrostatic charge virus, other than those of the S-protein. As that causes electrostatic repulsion from APC discussed below, a relatively simple way to membranes. 2. Masking of viral antigens by prepare multi-antigenic vaccine against glycans of the viral glycan-shield. various enveloped viruses, including SARS- Electrostatic repulsion- Internalization of CoV-2, is to use an inactivated whole-virus vaccinating virus into APC is mediated by vaccine processed to have increased random pinocytosis of small droplets immunogenicity by glycoengineering its containing the virus reaching close to the glycan-shield. surface area of these cells. Many of the N- glycans on viral envelope glycoproteins are Immunogenicity of enveloped whole-virus capped by the negatively charged vaccines carbohydrate sialic-acid (SA). O-glycans One of the major factors determining the (linked to serine or threonine) on the viral efficacy of whole-virus vaccines is the extent glycoproteins also carry SA.4-9 An example of uptake at the vaccination site of the of SA on N-glycans of a glycoprotein is vaccinating inactivated virus, by antigen illustrated as the left glycan in Figure 1. The presenting cells (APC) such as dendritic cells same glycans are present on APC and on other and macrophages. Once the vaccinating virus cells in the body. Thus, many vaccinating is internalized by APC, it is transported to virions that reach near the APC, close enough regional lymph nodes and processed for to be pinocytosed, are deflected because of the presentation
Load more

Recommended publications
  • Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza a Viruses
    viruses Review Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza A Viruses Tong Wang 1, Fanhua Wei 2 and Jinhua Liu 1,* 1 Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; [email protected] 2 College of Agriculture, Ningxia University, Yinchuan 750021, China; [email protected] * Correspondence: [email protected] Received: 22 July 2020; Accepted: 5 August 2020; Published: 7 August 2020 Abstract: Avian influenza A viruses (AIVs), as a zoonotic agent, dramatically impacts public health and the poultry industry. Although low pathogenic avian influenza virus (LPAIV) incidence and mortality are relatively low, the infected hosts can act as a virus carrier and provide a resource pool for reassortant influenza viruses. At present, vaccination is the most effective way to eradicate AIVs from commercial poultry. The inactivated vaccines can only stimulate humoral immunity, rather than cellular and mucosal immune responses, while failing to effectively inhibit the replication and spread of AIVs in the flock. In recent years, significant progresses have been made in the understanding of the mechanisms underlying the vaccine antigen activities at the mucosal surfaces and the development of safe and efficacious mucosal vaccines that mimic the natural infection route and cut off the AIVs infection route. Here, we discussed the current status and advancement on mucosal immunity, the means of establishing mucosal immunity, and finally a perspective for design of AIVs mucosal vaccines. Hopefully, this review will help to not only understand and predict AIVs infection characteristics in birds but also extrapolate them for distinction or applicability in mammals, including humans.
    [Show full text]
  • Development and Effects of Influenza Antiviral Drugs
    molecules Review Development and Effects of Influenza Antiviral Drugs Hang Yin, Ning Jiang, Wenhao Shi, Xiaojuan Chi, Sairu Liu, Ji-Long Chen and Song Wang * Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China; [email protected] (H.Y.); [email protected] (N.J.); [email protected] (W.S.); [email protected] (X.C.); [email protected] (S.L.); [email protected] (J.-L.C.) * Correspondence: [email protected] Abstract: Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal out- breaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treat- ment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some refer- ences for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.
    [Show full text]
  • Virus-Host Interactomics: New Insights and Opportunities for Antiviral Drug Discovery
    de Chassey et al. Genome Medicine 2014, 6:115 http://genomemedicine.com/content/6/11/115 REVIEW Virus-host interactomics: new insights and opportunities for antiviral drug discovery Benoît de Chassey1, Laurène Meyniel-Schicklin1, Jacky Vonderscher1, Patrice André2,3,4 and Vincent Lotteau3,4* Abstract The current therapeutic arsenal against viral infections remains limited, with often poor efficacy and incomplete coverage, and appears inadequate to face the emergence of drug resistance. Our understanding of viral biology and pathophysiology and our ability to develop a more effective antiviral arsenal would greatly benefit from a more comprehensive picture of the events that lead to viral replication and associated symptoms. Towards this goal, the construction of virus-host interactomes is instrumental, mainly relying on the assumption that a viral infection at the cellular level can be viewed as a number of perturbations introduced into the host protein network when viral proteins make new connections and disrupt existing ones. Here, we review advances in interactomic approaches for viral infections, focusing on high-throughput screening (HTS) technologies and on the generation of high-quality datasets. We show how these are already beginning to offer intriguing perspectives in terms of virus-host cell biology and the control of cellular functions, and we conclude by offering a summary of the current situation regarding the potential development of host-oriented antiviral therapeutics. Introduction the virus life-cycle. These proteins
    [Show full text]
  • To Download a Copy of Agencyiq's COVID-19 Development Tracker
    Development tracker: The drugs and vaccines in development for COVID-19 The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections. Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 140 medical product candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans. Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products is far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective. Highlights: 95+ 45+ 24+ 40+ Therapeutic medical Vaccines in development Products already approved Products already in clinical products in development for other indications development (6 vaccines, 34 therapies) Last updated 8 April 2020.
    [Show full text]
  • Influenza a Virus Superinfection Potential Is Regulated by Viral
    bioRxiv preprint doi: https://doi.org/10.1101/286070; this version posted March 21, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Influenza A virus superinfection potential is regulated 2 by viral genomic heterogeneity 3 4 Jiayi Sun1 and Christopher B. Brooke1,2* 5 6 1Department of Microbiology; University of Illinois, Urbana, IL 61801 7 2Carl R. Woese Institute for Genomic Biology; University of Illinois, Urbana, IL 61801 8 *Corresponding author ([email protected]) 9 10 Abstract 11 12 Defining the specific factors that govern the evolution and transmission of influenza A 13 virus (IAV) populations is of critical importance for designing more effective prediction and 14 control strategies. Superinfection, the sequential infection of a single cell by two or more 15 virions, plays an important role in determining the replicative and evolutionary potential of 16 IAV populations. The prevalence of superinfection during natural infection, and the 17 specific mechanisms that regulate it, remain poorly understood. Here, we used a novel 18 single virion infection approach to directly assess the effects of individual IAV genes on 19 superinfection efficiency. Rather than implicating a specific viral gene, this approach 20 revealed that superinfection susceptibility is determined by the total number of viral genes 21 expressed, independent of their identity. IAV particles that expressed a complete set of 22 viral genes potently inhibit superinfection, while semi-infectious particles (SIPs) that 23 express incomplete subsets of viral genes do not. As a result, virus populations that 24 contain more SIPs undergo more frequent superinfection.
    [Show full text]
  • Chenodeoxycholic Acid from Bile Inhibits Influenza a Virus Replication Via Blocking Nuclear Export of Viral Ribonucleoprotein Co
    molecules Article Chenodeoxycholic Acid from Bile Inhibits Influenza A Virus Replication via Blocking Nuclear Export of Viral Ribonucleoprotein Complexes Ling Luo 1, Weili Han 2, Jinyan Du 1, Xia Yang 1, Mubing Duan 3, Chenggang Xu 1, Zhenling Zeng 1, Weisan Chen 3,* and Jianxin Chen 1,* 1 Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China; [email protected] (L.L.); [email protected] (J.D.); [email protected] (X.Y.); [email protected] (C.X.); [email protected] (Z.Z.) 2 Hygiene Detection Center, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou 510515, China; [email protected] 3 Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia; [email protected] * Correspondence: [email protected] (W.C.); [email protected] (J.C.); Tel./Fax: +61-3-9479-3961 (W.C.); +86-20-8528-0234 (J.C.) Received: 19 October 2018; Accepted: 12 December 2018; Published: 14 December 2018 Abstract: Influenza A virus (IAV) infection is still a major global threat for humans, especially for the risk groups: young children and the elderly. The currently licensed antiviral drugs target viral factors and are prone to viral resistance. In recent years, a few endogenous small molecules from host, such as estradiol and omega-3 polyunsaturated fatty acid (PUFA)-derived lipid mediator protection D1 (PD1), were demonstrated to be capable of inhibiting IAV infection. Chenodeoxycholic acid (CDCA), one of the main primary bile acids, is synthesized from cholesterol in the liver and classically functions in emulsification and absorption of dietary fats.
    [Show full text]
  • Influenza Neuraminidase Operates Via a Nucleophilic Mechanism and Can
    ARTICLE Received 27 Sep 2012 | Accepted 15 Jan 2013 | Published 19 Feb 2013 DOI: 10.1038/ncomms2487 Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors Christopher J. Vavricka1,2,*, Yue Liu2,*, Hiromasa Kiyota3, Nongluk Sriwilaijaroen4,5, Jianxun Qi2, Kosuke Tanaka3, Yan Wu 2, Qing Li2,6, Yan Li2, Jinghua Yan2, Yasuo Suzuki5 & George F. Gao1,2,6,7 Development of novel influenza neuraminidase inhibitors is critical for preparedness against influenza outbreaks. Knowledge of the neuraminidase enzymatic mechanism and transition- state analogue, 2-deoxy-2,3-didehydro-N-acetylneuraminic acid, contributed to the devel- opment of the first generation anti-neuraminidase drugs, zanamivir and oseltamivir. However, lack of evidence regarding influenza neuraminidase key catalytic residues has limited strategies for novel neuraminidase inhibitor design. Here, we confirm that influenza neuraminidase conserved Tyr406 is the key catalytic residue that may function as a nucleophile; thus, mechanism-based covalent inhibition of influenza neuraminidase was conceived. Crystallographic studies reveal that 2a,3ax-difluoro-N-acetylneuraminic acid forms a covalent bond with influenza neuraminidase Tyr406 and the compound was found to possess potent anti-influenza activity against both influenza A and B viruses. Our results address many unanswered questions about the influenza neuraminidase catalytic mechanism and demonstrate that covalent inhibition of influenza neuraminidase is a promising and novel strategy for the development of next-generation influenza drugs. 1 Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science (BIOLS), Beijing 100101, China. 2 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
    [Show full text]
  • Towards a Universal Influenza Vaccine: Different Approaches for One Goal Giuseppe A
    Sautto et al. Virology Journal (2018) 15:17 DOI 10.1186/s12985-017-0918-y REVIEW Open Access Towards a universal influenza vaccine: different approaches for one goal Giuseppe A. Sautto1, Greg A. Kirchenbaum1 and Ted M. Ross1,2* Abstract Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre- pandemic strains.
    [Show full text]
  • Influenza a Virus Nucleoprotein: a Highly Conserved Multi-Functional Viral Protein As a Hot Antiviral Drug Target
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Curr Top Manuscript Author Med Chem. Author Manuscript Author manuscript; available in PMC 2018 May 24. Published in final edited form as: Curr Top Med Chem. 2017 ; 17(20): 2271–2285. doi:10.2174/1568026617666170224122508. Influenza A virus nucleoprotein: a highly conserved multi- functional viral protein as a hot antiviral drug target Yanmei Hu1, Hannah Sneyd1, Raphael Dekant1, and Jun Wang1,2,* 1Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ, 85721. U.S 2The BIO5 Institute, The University of Arizona, Tucson, AZ, 85721. U.S Abstract Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target.
    [Show full text]
  • Antiviral Research Tools
    Antiviral Research Tools Cayman provides a diverse set of antiviral agents that can be used to study the treatment and prevention of infectious diseases and other health challenges. This important set of tools can be used to further understand the growth cycle of harmful viruses and key signaling pathways, including how the body’s immune system responds to eliminate infections. Virus CONTINUE INSIDE THIS HOST BROCHURE TO EXPLORE: Receptor · Entry/Fusion Inhibitors Viral RNA is · Endosomal pH Regulators released into host · Protease & Neuraminidase Inhibitors Viral RNA · DNA & RNA Polymerase Inhibitors · Oxysterol-Binding Protein Inhibitors AAAAAAAA · Reverse Transcriptase Inhibitors Replication Protein Synthesis · Integrase Inhibitors Viral particles New viral mature particles assemble · Coronavirus Research Tools Spotlight New viruses are released from the host Host infection and viral replication. Simplify Screening & Hit-Seeking Antiviral Screening Library Item No. 30390 A library of more than 410 antiviral-associated compounds including those with antiviral activity against HIV, hepatitis B virus, coronaviruses, and more. SARS-CoV-2 Screening Library Item No. 9003509 A made-to-order compound library curated through in silico modeling using Maestro (Schrödinger Suite) software by screening over 70,000 compounds targeting SARS-CoV-2 proteins. 2021 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM Antiviral Compounds Protease & Neuraminidase Inhibitors Entry/Fusion Inhibitors Protease inhibitors block the viral life cycle by selectively preventing proteolytic cleavage that is essential to forming FEATURED PRODUCT the replicase complex for viral replication. Viral neuraminidase inhibitors prevent the mobilization of the virus to and Umifenovir (hydrochloride) from the site of infection.
    [Show full text]
  • Balancing the Influenza Neuraminidase and Hemagglutinin Responses by Exchanging the Vaccine Virus Backbone
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.08.416099; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone Jin Gao, Hongquan Wan, Xing Li, Mira Rakic Martinez, Yamei Gao, Zhiping Ye and Robert Daniels* Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA *Correspondence: [email protected] Running Title: Balancing the NA and HA antigen response Abstract Virions are a common antigen source for many viral vaccines. One limitation to using virions is that the antigen abundance is determined by the content of each protein in the virus. This caveat especially applies to viral-based influenza vaccines where the low abundance of the neuraminidase (NA) surface antigen remains a bottleneck for improving the NA antibody response. Here, we used the WHO recommended H1N1 antigens (2019-2020 season) in a systematic analysis to demonstrate that the NA to hemagglutinin (HA) ratio in virions can be improved by exchanging the viral backbone internal genes, thereby preserving the antigens. The purified inactivated virions with higher NA content show a more spherical morphology, a different balance between the HA receptor binding and NA receptor release functions, and induce a better NA inhibitory antibody response in mice.
    [Show full text]
  • Relative Affinity of the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase for Sialic Acid Correlates with Virus-Induced Fusion Activity
    JOUIRNALCOF VIROLOGY, Nov. 1993, p. 6463-6468 Vol. 67, No. 11 0022-538X/93/1 16463-06$02.00/() Copyright (© 1993, American Society for Microbiology Relative Affinity of the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase for Sialic Acid Correlates with Virus-Induced Fusion Activity ANNE MOSCONA"2* AND RICHARD W. PELUSO3 Departments of Pediatrics,' Cell Biology/Anatomy,2 and Microbiology,3 Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, New York 10029-6574 Received 8 July 1993/Accepted 2 August 1993 The ability of enveloped viruses to cause disease depends on their ability to enter the host cell via membrane fusion events. An understanding of these early events in infection, crucial for the design of methods of blocking infection, is needed for viruses that mediate membrane fusion at neutral pH, such as paramyxoviruses and human immunodeficiency virus. Sialic acid is the receptor for the human parainfluenza virus type 3 (HPF3) hemagglutinin-neuraminidase (HN) glycoprotein, the molecule responsible for binding of the virus to cell surfaces. In order for the fusion protein (F) of HPF3 to promote membrane fusion, the HN must interact with its receptor. In the present report, two variants of HPF3 with increased fusion-promoting phenotypes were selected and used to study the function of the HN glycoprotein in membrane fusion. Increased fusogenicity correlated with single amino acid changes in the HN protein that resulted in increased binding of the variant viruses to the sialic acid receptor. These results suggest that the avidity of binding of the HN protein to its receptor regulates the level of F protein-mediated fusion and begin to define one role of the receptor-binding protein of a paramyxovirus in the membrane fusion process.
    [Show full text]